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E-mail address: S.E.Radford@leeds.ac.uk (S.E. Radfob2-microglobulin (b2m) is a 99-residue protein that aggregates to form amyloid ﬁbrils in dialysis-
related amyloidosis. The protein provides a powerful model for exploration of the structural molec-
ular mechanisms of ﬁbril formation from a full-length protein in vitro. Fibrils have been assembled
from b2m under both low pH conditions, where the precursor is disordered, and at neutral pH where
the protein is initially natively folded. Here we discuss the roles of sequence and structure in amy-
loid formation, the current understanding of the structural mechanisms of the early stages of aggre-
gation of b2m at both low and neutral pH, and the common and distinct features of these assembly
pathways.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction
The aggregation of proteins into amyloid ﬁbrils has been stud-
ied in detail for more than 50 years, yet elucidation of the exact
structural mechanisms of this process still provides a considerable
challenge [1]. The heterogeneous nature of the protein aggregation
landscape contributes to the complexity of this problem. Indeed,
even at the earliest stage of this process the monomeric precursors
of amyloid formation can be found as a complex mixture that can
include natively folded, partially folded and highly unfolded pro-
tein species, any one of which could initiate the aggregation pro-
cess. Furthermore, since the inter- and intra-molecular
interactions that are involved in aggregation and protein folding
are similar, much work remains to improve our understanding of
the competition between these events, especially at the initial
stages of amyloid formation (Fig. 1A) [2]. Moreover, multiple prac-
tical challenges exist as the formation of ﬁbrils is stochastic and
many of the species populated en route to the ﬁbril product are
unstable and only transiently formed. Understanding the biophys-
ical nature of amyloid formation, however, is an important goal,
not only because a number of diseases involve the deposition of
amyloid ﬁbrils [3], but also because the ability to form amyloid iscal Societies. Published by Elsevier
NMR, nuclear magnetic reso-
rd).known to be a fundamental property of all polypeptide chains un-
der the appropriate conditions, independent of sequence [4]. How-
ever, the manner in which the generic cross-b structure of amyloid
is accommodated by the differing sequences of proteins within
their ﬁbrillar architecture is not yet understood.
To comprehend the process of amyloid ﬁbril formation in atom-
istic detail much work has been performed on a range of proteins
in vitro. Here, we review some of the techniques employed and the
results obtained in the study of the structural and molecular mech-
anisms of ﬁbril formation of the protein b2-microglobulin (b2m).
This protein folds natively into a b-sandwich fold consisting of
two b-sheets, one containing four strands (ABED) and the other
three (CFG) (Fig. 1B) [5]. A disulphide bond between two cysteines
(residues 25 and 80) covalently links these sheets [5]. Intact wild-
type b2m is the major component of amyloid ﬁbrils deposited in
the joints of patients on long-term haemodialysis, in a condition
known as dialysis-related amyloidosis (DRA). In vivo, b2m is the
non-covalently attached light chain of the human major histocom-
patibility complex 1 (MHC1) [5]. Naturally, b2m is shed into the
serum and degraded by the kidneys, maintaining the serum b2m
concentrations at 0.09–0.17 lM in healthy individuals [6]. How-
ever, in patients with renal failure the haemodialysis membrane
is unable to remove b2m, resulting in increases in the serum con-
centration by up to 60-fold [7]. This rise in concentration alone is
deemed not to be sufﬁcient for ﬁbril formation [8]. Thus other, as
yet unknown, contributing factors lead to deposition of the full-
length b2m as amyloid ﬁbres in the synovium of joints.B.V.Open access under CC BY license.
Fig. 1. (A) Schematic illustration of the competition between intra-molecular and inter-molecular interactions in protein folding and assembly. When intra-molecular
interactions prevail, proteins fold or form collapsed states (left side). By contrast, when inter-molecular interactions dominate, protein aggregation results (right side). (B)
Monomeric b2mwith residues discussed herein highlighted. (C) Amyloid forming properties of the sequence of b2m when isolated as peptides [10–15], or in the context of the
full-length protein (the latter at pH 2.5). Red circles indicate residues that affect ﬁbril formation kinetics, blue circles indicate positions where changes had little or no effect
on kinetics [19]. (D) Structure of b2m (gold) in the MHC-1 complex. Hydrophobic residues present in the b-strand E region of b2m (Phe56, Trp60, Tyr62, Tyr63 and Leu65) that
contact the heavy chain of the MHC-1 are highlighted.
2624 G.W. Platt, S.E. Radford / FEBS Letters 583 (2009) 2623–2629Here we consider the current state of research into the mecha-
nism of b2m ﬁbril formation in vitro. We discuss the ﬁbril forma-
tion pathways under different conditions, how they may be
related to one another and to the mechanism occurring in vivo;
and how the amyloid forming potential of b2m is modulated by se-
quence and structural changes.
2. Sequence versus structural determinants of ﬁbril formation
Studies using prediction algorithms and peptide models have
indicated that 60% of the sequence of b2m is highly amyloido-
genic (Fig. 1C) [9–15]. However, the innate amyloid forming poten-
tial of the polypeptide sequence of b2m is modulated by structure,
as the natively folded protein is impervious to aggregation [8,16].
At least a partial unfolding event must therefore take place
in vivo to allow exposure of one or more aggregation-prone re-
gion(s) of the sequence to initiate amyloid formation. To study ﬁ-
bril formation of b2m in vitro, many destabilising conditions have
been applied, by adding co-solvents, detergents or denaturants at
neutral pH or by reducing the pH to drive the aggregation process
on a biophysically feasible timescale [17].
At low pH (<pH 3.0), low ionic strength (650 mM) and encour-
aged by agitation, b2m spontaneously aggregates in vitro to formﬁbrils with all of the hallmarks of amyloid [16]. Kinetic analyses
of ﬁbril growth coupled with a mutational screen have indicated
that a single region approximately 10 residues in length (60–
70) is important for determining the rate of ﬁbril nucleation and
elongation of the full-length protein under these conditions
(Fig. 1C) [18,19]. This region of the sequence is enriched in aro-
matic residues and is predicted to be highly aggregation-prone
by amyloid algorithms [9]. Other studies of the full-length b2m se-
quence at low pH have indicated that its ability to form amyloid is
related to the stability of the ﬁbrils and that introduction of the b-
sheet breaking amino acid, Pro, in place of certain residues, espe-
cially Leu23, His51 or Val82, causes a reduction in ﬁbril elongation
kinetics [20]. Comparison of the effects of sequence alteration on
the ﬁbril growth kinetics of the intact, oxidised protein at low pH
with the results of peptide studies is striking. While fragments cor-
responding to three regions (residues 20–40, 60–70 and 80–99)
all form amyloid in isolation [10–15,19], in the context of the
full-length protein chain mutation of residues in only one region
(60–70) alters the ﬁbril formation kinetics (Fig. 1C) [18,19]. One
explanation of this observation is that structure in the initial dena-
tured state may modulate the amyloid potential of the polypeptide
chain, even when the initial amyloid precursor is highly unfolded
(Fig. 1A) [19]. Indeed, nuclear magnetic resonance (NMR) analysis
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residual structure, stabilised by the disulphide bond, which in-
volves the clustering of hydrophobic residues in two regions (29–
51 and 58–79) [21]. Therefore, even in this highly dynamic species
the amyloid forming potential of the sequence may be modulated
by structure, with the result that only one short stretch of residues
(60–70) determines the aggregation potential of the entire 99-
residue sequence. Examination of the crystal structure of b2m in
the MHC class I complex illustrates why the protein may contain
such a highly aggregation-prone sequence. Aromatic residues
including Phe56, Trp60, Phe62 and Tyr63 (as well as the hydropho-
bic residue Leu65), which all lie in the aggregation-determining se-
quence, make important contacts with the MHC I heavy chain
(Fig. 1D) [5]. Indeed, mutation of Trp60 to Gly results in a weak-
ened interaction with the heavy chain, and a more stable native
state that is less aggregation-prone [22]. This part of the sequence
thus appears to have evolved for functional reasons (maintenance
of the immune system) without consideration of the consequences
for aggregation.
3. Structural mechanisms of the early events in b2m aggregation
at pH 2.5
At low pH b2m ﬁbril formation proceeds rapidly from a highly
dynamic state with lag-dependent kinetics [16,23], indicative of a
nucleation-dependent mechanism. Mass spectrometry data indi-
cates that small oligomers including dimers, trimers and tetramers
(but no larger assemblies) are observed to form during the lag time
of the aggregation process (Fig. 2) [24]. That higher order assem-
blies are not detected implies that larger oligomers may rapidly
aggregate into ﬁbrils, or such species may not be detectable by
mass spectrometry. Numerical modelling studies of the kinetics
of ﬁbril formation at different protein concentrations, which in-
cluded over 20 different possible assembly mechanisms, suggest
that the initial molecular recognition events involve the assembly
of monomers leading to the formation of a high-energy structural
nucleus consisting of six b2m polypeptide chains. Elongation then
proceeds rapidly to form amyloid-like ﬁbres by monomer addition
[23]. Structural detail of the observed oligomers is sparse but little
ordered secondary structure is observed by FTIR [25], and theseFig. 2. Species formed en route to amyloid ﬁbrils by b2m at pH 2.5 as monitored by
mass spectrometry and ThT ﬂuorescence. During the lag phase (blue line, bottom
ﬁgure), the concentration of monomeric protein (red circles) decreases more rapidly
than expected based on ThT data (grey line). ESI-MS data (top) shows the presence
of dimers, trimers and tetramers as well as monomers, but no larger species, during
the lag phase. At the conclusion of the reaction no oligomers remain. Data were
taken from Smith et al. [24].species do not bind the antibody A11 (unpublished data), which
has commonly been used to detect toxic oligomers that form en
route to amyloid ﬁbrils from many different proteins [26]. Pres-
ently, the structural role of the aromatic-rich region involving res-
idues 60–70 in these early assembly intermediates is unknown
[18,19], although previous studies have noted the importance of
aromatic stacking interactions in amyloid formation [27].
Information towards understanding the elongation of b2m ﬁ-
brils was gained in a study at pH 2.5 by total internal reﬂection
ﬂuorescence microscopy, which indicated that this process is uni-
directional when the ﬁbrils are ﬁxed on a glass surface, implying a
polarised aggregation mechanism [28]. Interestingly, this method
also indicated that ﬁbrils elongate at a range of rates suggesting
a variety of structural differences in the long-straight amyloid
structures formed at pH 2.5 and highlighting the complexities of
studying amyloid ﬁbril formation whereby different ﬁbril struc-
tures co-exist at equilibrium that are difﬁcult to discern without
recourse to detailed structural analysis.4. A structural trigger at neutral pH?
To mimic conditions that are more physiologically relevant,
studies in vitro have adopted a number of methods to drive amy-
loid formation of b2m at neutral pH, since the protein is initially
natively folded at pH 7. Biological components, including glycos-
aminoglycans, proteoglycans, collagen and Cu2+ (the latter in the
presence of 1 M urea) have all been used to promote, or induce, ﬁ-
bril formation at neutral pH in vitro [8,29–31]. In addition, co-sol-
vents such as TFE or SDS, alteration of the physical environment by
ultrasonication, elevated temperature or stirring at high concentra-
tions of salt induce ﬁbril formation from wild-type b2m at, or close
to, neutral pH [32–35]. Alterations of the protein sequence have
also been used to stimulate the formation of ﬁbrils at neutral pH.
Speciﬁcally, truncation of six residues from the N-terminal region
(DN6), as well as mutation in this region (P5G) or in the B/C or
D/E loops (P32A, P32G, D59P) of the protein all enhance its ability
to form amyloid in vitro (Fig. 3), while substitutions elsewhere in
the protein have little effect [31,36–38]. These studies have the
common feature that they encourage partial unfolding of b2m,
allowing the aggregation-prone regions of the polypeptide se-
quence to be exposed and to participate in intermolecular
interactions.
The b2m variants, P32G and P32V, have been used to show that
wild-type b2m populates a native-like folding intermediate (called
IT) en route to the native state that contains a non-native trans
Pro32 bond [37,39,40]. Increased population of this intermediate
in the variant P32G was shown to be concomitant with increased
ability of the protein to elongate b2m ﬁbril seeds [37]. Interest-
ingly, it may be that a speciﬁc trans Pro32 residue is important
for b2m to nucleate amyloid ﬁbrils at neutral pH, as both P32G
and P32V b2m which form trans Gly32 or Val32 cannot form amy-
loid-like ﬁbrils spontaneously, although P32G can elongate stabi-
lised seeds more efﬁciently than wild-type b2m under the
conditions employed [37,40]. Other variants, such as P5G and
DN6, also affect isomerisation of the Pro32 peptide bond, promot-
ing population of IT and enabling ﬁbril nucleation at pH 7.0 [36]. In
separate studies b2m has been shown to form oligomers and ﬁbrils
at neutral pH by addition of Cu2+ and 1 M urea [8,31]. This induces
the formation of a non-native species, called M*, that appears iden-
tical to IT by size exclusion chromatography (SEC) [36]. Coordina-
tion of the metal ion promotes peptide bond isomerisation at
Pro32 [31], and the subsequent rapid formation of oligomers as
judged by SEC, providing further supporting evidence that the
isomerisation of Pro32 is a key initial step on the pathway to ﬁbrils
[8,31,36].
Fig. 3. Structures of wild-type b2m and several variants mentioned herein, blue
spheres show the site of mutation where relevant. Regions of major conformational
change are highlighted. (A) WT b2m in the MHC-1 complex (PDB: 1DUZ) [5]. (B)
P32A variant of b2m that crystallises as a dimer and forms digomers in the presence
of Cu2+ (2F8O) [31]. (C) Model of structural changes in a folding intermediate of
b2m, populated at high levels in the P32G variant, mapped onto the NMR structure
of wild-type b2m. Regions that are most perturbed in comparison with wild-type
b2m are shown in red, those that show little perturbation are pink and no
information is available for those in grey [37]. (D) X-ray crystallographic structure
of a rare monomeric species of wild-type b2m with a straight b-strand D (1LDS)
[44]. (E) W60G variant of b2m that has a decreased amyloid propensity (2Z9T) [22].
(F) D59P b2m displays an increased propensity to form amyloid (3DHJ) [38].
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have provided molecular insights into the possible aggregation
mechanisms of b2m at neutral pH. Burst-phase amplitudes from
real-time NMR studies of b2m folding indicate that residues distal
to Pro32 maintain native-like structure in the intermediate, while
regions proximal to Pro32 in the B/C loop are disordered until trans
to cis isomerisation of the Pro32 peptide bond takes place [40].
Consistent with this, studies of P32G by NMR have shown that res-
idues in the B/C loop, the adjacent F/G loop and the edge b-strands
A and D are altered in the intermediate IT (Fig. 3). Crystallographic
data for a mutant, P32A, that populates the native-like M* state at
neutral pH, shows that this conformer results in substantial reorga-
nisation of aromatic side-chains that are present in the core of the
native protein [31]. In this structure, a number of aromatic and
hydrophobic residues are displaced including Phe30, Phe56,
Trp60, Phe62, Tyr63 and Leu54. These rearrangements present a
strip of exposed hydrophobic residues on the protein surface, pro-
viding a possible avenue for protein aggregation. Furthermore, the
structural changes lead to alterations in the organisation of resi-
dues 52–56, including abolition of the b-bulge that is present in
the native b-strand D and is a deterrent to edge strand aggregation
(Fig. 3) [41]. This species crystallises as a dimer underlining its po-
tential to form intermolecular interactions [31].
Other regions of the b2m sequence have been proposed to mod-
ulate ﬁbril formation at neutral pH and do not involve isomerisa-
tion of the Pro32 peptide bond. Substitution of Trp60 in the D/E
loop with Gly increases the stability of the native state and reduces
the ability of the protein to aggregate at neutral pH in the presence
of TFE [22]. Removal of this large, hydrophobic side chain will not
only reduce the inherent aggregation potential of the protein chain
but, by decreasing strain in the loop region adjacent to the aro-
matic-rich, amyloidogenic sequence of b-strand E [18], the nativestate is stabilised, hence further reducing its ability to aggregate
(Fig. 3). Indeed, a D59P variant that increases strain in the D/E loop
region and reduces protein stability shows an increased potential
to form ﬁbrils (Fig. 3) [38].
5. A common ﬁbrillar architecture is formed from diverse
precursors
Akin to a protein folding landscape, aggregation into amyloid
may be achieved via a number of routes. In aqueous conditions
at pH 2.5 and 7.0 amyloid-like ﬁbrils are formed from b2m that
show a long-straight, left-hand twisted and unbranched morphol-
ogy when observed by EM and AFM (Fig. 4A) [42]. Fibrils formed at
both pH values bind the amyloid-speciﬁc dyes ThT and Congo Red;
display characteristic cross-b structure as evidenced by X-ray ﬁbre
diffraction (Fig. 4A) and exhibit an identical b-sheet content when
studied by FTIR [42]. However, some differences between the ﬁ-
brils must exist as those formed at pH 2.5 depolymerise at pH 7 un-
less stabilised by co-factors such as glycosaminoglycans [29].
Comparison of the ﬁbrils formed at pH 2.5 and 7.0 by FTIR, a tech-
nique that is highly sensitive to the length and twist of b-strands,
suggests that the polypeptide chain is ordered in a similar parallel
fashion in both ﬁbril types [25,42]. These structural similarities are
shared by ex vivo ﬁbrils obtained from DRA patients, implying that
study of the processes that lead to ﬁbrils in vitro under aqueous
conditions, even at low pH, may provide relevant information
about the formation of ﬁbrils in disease. These ﬁndings beg the
question of how similar the assembly pathways are and whether
these separate pathways converge to form a common ﬁbrillar
product (Fig. 4B). Interestingly, however, the ﬁbrils produced in
the presence of SDS or TFE show distinct morphological properties,
compared with those formed in the absence of these additives at
neutral pH, suggesting that alternative conformations of the ﬁbres
(polymorphs) can be formed by ﬁne tuning of the solution condi-
tions [32,43].6. Progress towards a unifying mechanism of b2m ﬁbril
formation
One of the most striking observations of the b2m assembly
pathways is that the ﬁbrils formed commencing from a highly
denatured state or a native-like precursor are apparently indistin-
guishable, suggesting that their assembly pathways must converge
to a similar ﬁbrillar product. This could occur by unfolding of na-
tive b2m to allow reorganisation of the protein structure; or by
refolding of the highly dynamic polypeptide chain at pH 2.5 to a
more structurally ordered intermediate species (Fig. 4B). The kinet-
ics of ﬁbril formation suggest that the acid unfolded precursor can
readily access a critical aggregation-prone species, since amyloid
formation proceeds rapidly (within hours) under these conditions
[18,23]. By contrast, at pH 7, even in the presence of ﬁbril seeds, ﬁ-
bril formation takes weeks [36]. Similarities between the assembly
mechanisms are supported by the proposal that aromatic interac-
tions are crucial for driving ﬁbrillogenesis under both sets of con-
ditions [12,18,19,31]. Indeed, the dimeric structure of M* [31],
indicates that interactions between speciﬁc and structurally organ-
ised hydrophobic and aromatic residues may lead to ﬁbrillation.
Moreover, removal of the b-bulge from b-strand D, as observed
for many of the ﬁbril-forming variants of b2m formed at neutral
pH (Fig. 3), could provide a site for productive intermolecular edge
strand interactions. Interestingly, a rare conformer of wild-type
b2m with a straightened b-strand D has been observed in crystal-
lography studies (Fig. 3) [44]. Whilst this wild-type conformer
has different sidechain organisation to that observed for the vari-
ants capable of forming ﬁbrils at neutral pH (P32A, D59P) it pro-
Fig. 4. (A) Comparison of experimental data for ﬁbrils of b2m formed at pH 7.0 and 2.5. EM scale bar indicates 100 nm. Absorbance spectra of Congo Red free in solution (black
line) and bound to b2m ﬁbrils (red line) as well as the difference spectra (inset). Both ﬁbril types give rise to red-green birefringence in the presence of Congo Red. The X-ray
ﬁbre diffraction patterns show reﬂections at 4.7 Å and 10 Å, consistent with a cross-b structure. Data were taken from Jahn [50]. (B) Scheme for convergence of the
mechanisms of ﬁbril formation at pH 2.5 and 7.0. Regions with high amyloidogenic propensity are displayed in pink. It is not known precisely how oligomers stack or whether
they have ordered b-sheet, however, increased intermolecular protein–protein interactions (red) may be important in the reaction pathway.
G.W. Platt, S.E. Radford / FEBS Letters 583 (2009) 2623–2629 2627vides evidence (alongside that of other variants, such as W60G)
[22,43] that this edge strand straightening is not sufﬁcient to pro-
mote ﬁbril growth. Another convergent feature arises from a sug-
gested model for the ﬁbrils formed at neutral pH that contains a
highly charged surface [31], which could be neutralised at low
pH, perhaps allowing for a convergence of the mechanisms of
assembly at acidic and neutral pH and explaining why the kinetics
of ﬁbril formation are much more rapid under acidic conditions. An
additional common characteristic is that many variants capable of
ﬁbril formation at neutral pH have the effect of destabilising the N-
terminal region of the protein [31,37,40], which is also highly un-
folded in the structural ensembles formed at low pH [21]. The dis-
ruption of this region has been proposed as key to amyloid
formation [45]. Indeed, the double variant, P32G/I7A that combines
a trans peptide bond at Pro32 with destabilisation of the N-termi-
nal region forms ﬁbrils spontaneously at neutral pH [42]. The role
of trans Pro32 in ﬁbril formation at low pH is currently unknown,
although 80% of the molecules would be expected to contain
the trans conformation in the acid denatured state [46]. Moreover,
the observation that the rate of ﬁbril formation of P32G is similarto that of wild-type b2m when studied at pH 2.5 is suggestive of
a common trans amyloid precursor [19].
The possibility that partial or global unfolding of the initially
folded monomer of b2m is required for ﬁbrillogenesis at neutral
pH is supported by data from a variant of b2m that is cleaved at
Lys58 (DK58), adjacent to the aromatic-rich, aggregation-prone re-
gion (60–70), and retains a native fold in vitro [47]. This variant is
ﬁbrillation-prone under conditions similar to those found in vivo
(<pH 6.8), where it more frequently populates a highly unprotected
state [48]. The aggregation-competent species formed in these
studies must, however, contain some speciﬁc structural attributes
as simply creating a variant of b2m that is highly unstable and fre-
quently visits an unfolded state (such as V37A) does not engender
amyloidogenicity alone [49].
7. Summary and outlook
Studies of the molecular mechanisms of b2m aggregation both
under denaturing and native conditions have provided important
new insights into the structural changes associated with ﬁbril for-
2628 G.W. Platt, S.E. Radford / FEBS Letters 583 (2009) 2623–2629mation for this protein that may have relevance for understanding
amyloid in general. The sequence of b2m has a high amyloid form-
ing potential as inferred from aggregation prediction algorithms
and peptide studies [9–15]. However, work on the full-length pro-
tein indicates that the aggregation potential of this sequence is
highly modulated by structure, not just in the native state, wherein
the aggregation-prone regions are completely sequestered in the
native core, but also in the highly dynamic acid unfolded state.
Thus, whilst peptide fragment studies are of great utility in
answering fundamental questions regarding amyloid formation,
their study in context of full-length proteins can be misleading.
The fact that many different proteins with unrelated sequences
and native folds can all form amyloid-like ﬁbrils with nucleation-
dependent kinetics implies the possibility of a common mecha-
nism. The ﬁnding that b2m can form similar long-straight amy-
loid-like ﬁbrils commencing from two very different structural
states reinforces the view of a generic assembly mechanism. Under
each set of conditions similar hydrophobic and aromatic regions of
the sequence appear to be key to the aggregation mechanism.
While reducing the stability of the native fold and increasing global
or subglobal unfolding events is important in initiating amyloid
formation, some structural preference, for instance the presence
of a non-native trans Pro32, is clearly linked to the ability to aggre-
gate. Even in the acid unfolded state it appears that speciﬁcally
structured species presenting aggregation-prone regions are re-
quired for amyloid formation, whilst other transiently structured
regions may modulate aggregation by sequestering sequences with
high amyloid forming potential.
It is currently unclear whether the same oligomeric species are
populated during assembly at acidic and at neutral pH and future
endeavours will need to focus on the structural properties of the
oligomers that form as aggregation proceeds. Such studies may
provide clues as to how ﬁbrillation can be impeded therapeutically
and how ﬁbril formation proceeds mechanistically. Indeed, whilst
oligomers are commonly observed during ﬁbril formation, there
is as yet no deﬁnitive proof that such species are on pathway to
the ﬁbrillar form. Furthermore, atomistic insights into the struc-
ture of b2m amyloid ﬁbrils will be required to provide unequivocal
evidence for the convergence of the assembly pathways at pH 2.5
and 7.0 and to provide detailed information as to whether the pro-
tein is completely refolded in the ﬁbril structure or retains rem-
nants of its native fold. Towards this goal recent cryo-EM studies
have shown a remarkably complex architecture for the ﬁbrils
formed from b2m at pH 2.5 [51]. Ultimately, as the studies on
b2m have helped to conﬁrm, the amyloid-forming potential of a
protein is clearly a function of how structure modulates the intrin-
sic b-aggregation propensity of the amino acid sequence, not just
for the natively folded protein but also for proteins that aggregate
from highly unfolded initial precursor states.
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